deucravacitinib,apremilast
BMS,Amgen
['psoriasis', '#2134', 'deucra']
warren et al. tyk2i deucravacitinib in plaque psoriasis at 2 years. sustained efficacy. no new safety signals seen. #acr22 abstr#2134 
Rheumatologist @stjamesdublin , Associate Professor @tcddublin , Acute Medicine, Vasculitis, ILD, Retired @Emeunet Executive Committee member, @rheum_covid CASC